PMID- 11746532
OWN - NLM
STAT- MEDLINE
DCOM- 20020304
LR  - 20191105
IS  - 0733-2459 (Print)
IS  - 0733-2459 (Linking)
VI  - 16
IP  - 2
DP  - 2001
TI  - Dynamic changes in cytokine levels in serum and synovial fluid following 
      filtration leukocytapheresis therapy in patients with rheumatoid arthritis.
PG  - 74-81
AB  - We attempted to determine whether various cytokine levels in the serum and 
      synovial fluid (SF) of rheumatoid arthritis (RA) patients are influenced by the 
      performance of filtration leukocytapheresis (LCP). The filtration LCP procedure 
      that used a Cellsorba column (LCP group: n=22; responder subgroup: n=17, 
      non-responder subgroup: n=5) or sham apheresis (control group; n=7) was repeated 
      three times at 1-week intervals. Serum (LCP group, n=22; control group, n=7) and 
      SF (LCP group, n=6; control group, n=3) samples were collected before and after 
      LCP. Levels of tumor necrosis factor alpha (TNFalpha), interleukins (IL-1 beta, 
      IL-2, IL-6, IL-8, IL-10, and IL-15), granulocyte-macrophage colony-stimulating 
      factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), RANTES were measured 
      by an enzyme-linked immunosorbent assay. Serum TNF alpha, IL-15, and RANTES were 
      significantly reduced only in the LCP group. Serum IL-10 significantly increased 
      only in the LCP group. In the LCP subgroup, serum IL-15, GM-CSF, and RANTES 
      levels were reduced significantly, while serum IL-10 levels increased 
      significantly only in the responder group after treatment. Serum TNF alpha levels 
      were reduced significantly in both subgroups. Changes in serum IL-10 correlated 
      positively with the improvement of patient's assessment of pain and global 
      severity, and physician's assessment of global severity. These results indicate 
      that the removal of leukocytes from the peripheral blood of RA patients provokes 
      dynamic changes in some cytokine levels in the serum and/or synovial fluid. These 
      changes may explain some of the mechanisms by which the articular symptoms are 
      improved by filtration LCP.
CI  - Copyright 2001 Wiley-Liss, Inc.
FAU - Hidaka, T
AU  - Hidaka T
AD  - Internal Medicine I, National Defense Medical College, Tokorozawa, Saitama, 
      Japan.
FAU - Suzuki, K
AU  - Suzuki K
FAU - Kawakami, M
AU  - Kawakami M
FAU - Okada, M
AU  - Okada M
FAU - Kataharada, K
AU  - Kataharada K
FAU - Shinohara, T
AU  - Shinohara T
FAU - Takamizawa-Matsumoto, M
AU  - Takamizawa-Matsumoto M
FAU - Ohsuzu, F
AU  - Ohsuzu F
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Clin Apher
JT  - Journal of clinical apheresis
JID - 8216305
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL5)
RN  - 0 (Cytokines)
RN  - 0 (Interleukins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 81627-83-0 (Macrophage Colony-Stimulating Factor)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Adult
MH  - Arthritis, Rheumatoid/blood/*therapy
MH  - Autoimmune Diseases/blood/*therapy
MH  - Chemokine CCL2/blood
MH  - Chemokine CCL5/blood
MH  - Cytokines/*analysis/blood
MH  - Double-Blind Method
MH  - Female
MH  - Filtration
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/blood
MH  - Humans
MH  - Interleukins/blood
MH  - *Leukapheresis/instrumentation/methods
MH  - Macrophage Colony-Stimulating Factor/blood
MH  - Male
MH  - Middle Aged
MH  - Synovial Fluid/*chemistry
MH  - Th1 Cells/metabolism
MH  - Th2 Cells/metabolism
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/analysis
EDAT- 2001/12/18 10:00
MHDA- 2002/03/05 10:01
CRDT- 2001/12/18 10:00
PHST- 2001/12/18 10:00 [pubmed]
PHST- 2002/03/05 10:01 [medline]
PHST- 2001/12/18 10:00 [entrez]
AID - 10.1002/jca.1016 [pii]
AID - 10.1002/jca.1016 [doi]
PST - ppublish
SO  - J Clin Apher. 2001;16(2):74-81. doi: 10.1002/jca.1016.